Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALXO Analyst Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALXO Stock 12 Month Forecast
Average Price Target
$2.00
▲(81.82% Upside)
| Highest Price Target$2.00 | Average Price Target$2.00 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
―
Hold
―
Reiterated
08/15/25
ALX Oncology Holdings (ALXO) Receives a Hold from LifeSci CapitalALX Oncology this week hosted a conference call (LINK to presentaon) to discuss Q2 2025 earnings and provide an update on the development of evorpacept (CD47 blocker, high-affinity SIRPa fused to an inacve Fc) and ALX2004 (EGFR targeng ADC).
H.C. Wainwright
$2
Buy
81.82%
Upside
Reiterated
08/13/25
ALX Oncology Holdings: Strategic Focus and Promising Developments Drive Buy RatingValuation and Risks. We maintain our Buy rating on ALXO and our 12-month price target of $2.00 per diluted share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from evorpacept, assuming a 12% discount rate and a 0% terminal growth rate. We derive an rNPV of $293M and add in net cash and cash equivalents of approximately $69.2M, to arrive at a 12-month price target of $2.05 per diluted share, which we round to $2.00. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property.
Piper Sandler
$3
Buy
172.73%
Upside
Reiterated
05/21/25
UBS
$1.2→$1
Buy
-9.09%
Downside
Reiterated
05/21/25
Jefferies
$3
Buy
172.73%
Upside
Reiterated
05/08/25
TR | OpenAI - 4o
―
Sell
―
Reiterated
04/22/25
Stifel Nicolaus
$3→$1.5
Hold
36.36%
Upside
Reiterated
03/07/25
Cantor Fitzgerald
―
Buy
―
Reiterated
01/24/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
―
Hold
―
Reiterated
08/15/25
ALX Oncology Holdings (ALXO) Receives a Hold from LifeSci CapitalALX Oncology this week hosted a conference call (LINK to presentaon) to discuss Q2 2025 earnings and provide an update on the development of evorpacept (CD47 blocker, high-affinity SIRPa fused to an inacve Fc) and ALX2004 (EGFR targeng ADC).
H.C. Wainwright
$2
Buy
81.82%
Upside
Reiterated
08/13/25
ALX Oncology Holdings: Strategic Focus and Promising Developments Drive Buy RatingValuation and Risks. We maintain our Buy rating on ALXO and our 12-month price target of $2.00 per diluted share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from evorpacept, assuming a 12% discount rate and a 0% terminal growth rate. We derive an rNPV of $293M and add in net cash and cash equivalents of approximately $69.2M, to arrive at a 12-month price target of $2.05 per diluted share, which we round to $2.00. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property.
Piper Sandler
$3
Buy
172.73%
Upside
Reiterated
05/21/25
UBS
$1.2→$1
Buy
-9.09%
Downside
Reiterated
05/21/25
Jefferies
$3
Buy
172.73%
Upside
Reiterated
05/08/25
TR | OpenAI - 4o
―
Sell
―
Reiterated
04/22/25
Stifel Nicolaus
$3→$1.5
Hold
36.36%
Upside
Reiterated
03/07/25
Cantor Fitzgerald
―
Buy
―
Reiterated
01/24/25
Best Analysts Covering ALX Oncology Holdings
1 Month
xxx
Success Rate
7/16 ratings generated profit
Average Return
+4.03%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 43.75% of your transactions generating a profit, with an average return of +4.03% per trade.
3 Months
xxx
Success Rate
5/9 ratings generated profit
Average Return
+1.91%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +1.91% per trade.
1 Year
Success Rate
5/16 ratings generated profit
Average Return
-9.69%
reiterated a buy rating 15 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of -9.69% per trade.
2 Years
xxx
Success Rate
3/16 ratings generated profit
Average Return
-41.76%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 18.75% of your transactions generating a profit, with an average return of -41.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALXO Analyst Recommendation Trends
Rating
Jan 25
Mar 25
Apr 25
May 25
Aug 25
Strong Buy
3
5
6
11
9
Buy
1
1
1
0
0
Hold
13
13
8
4
3
Sell
3
2
2
2
1
Strong Sell
0
0
0
0
0
total
20
21
17
17
13
Each month's total comprises the sum of three months' worth of ratings.
ALXO Financial Forecast
ALXO Stock Forecast FAQ
What is ALXO’s average 12-month price target, according to analysts?
Based on analyst ratings, ALX Oncology Holdings’s 12-month average price target is 2.00.
What is ALXO’s upside potential, based on the analysts’ average price target?
ALX Oncology Holdings has 81.82% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALXO a Buy, Sell or Hold?
ALX Oncology Holdings has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
What is ALX Oncology Holdings’s price target?
The average price target for ALX Oncology Holdings is 2.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $2.00 ,the lowest forecast is $2.00. The average price target represents 81.82% Increase from the current price of $1.1.
The highest analyst price target is $2.00 ,the lowest forecast is $2.00. The average price target represents 81.82% Increase from the current price of $1.1.
What do analysts say about ALX Oncology Holdings?
ALX Oncology Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of ALXO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.